• Welcome to Phoenix Rising!

    Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of and finding treatments for complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia (FM), long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.

    To become a member, simply click the Register button at the top right.

In vivo-generated antigen-specific regulatory T cells treat autoimmunity


Senior Member
Sci Transl Med. 2014 Jun 18;6(241):241ra78.
In vivo-generated antigen-specific regulatory T cells treat autoimmunity without compromising antibacterial immune response.
Kasagi S1, Zhang P1, Che L1, Abbatiello B1, Maruyama T1, Nakatsukasa H1, Zanvit P1, Jin W1, Konkel JE1, Chen W2.

Harnessing regulatory T (Treg) cells is a promising approach for treating autoimmune disease. However, inducing antigen-specific Treg cells that target inflammatory immune cells without compromising beneficial immune responses has remained an unmet challenge.

We developed a pathway to generate autoantigen-specific Treg cells in vivo, which showed therapeutic effects on experimental autoimmune encephalomyelitis and nonobese diabetes in mice. Specifically, we induced apoptosis of immune cells by systemic sublethal irradiation or depleted B and CD8(+) T cells with specific antibodies and then administered autoantigenic peptides in mice with established autoimmune diseases.

We demonstrated mechanistically that apoptotic cells triggered professional phagocytes to produce transforming growth factor-β, under which the autoantigenic peptides directed naïve CD4(+) T cells to differentiate into Foxp3(+) Treg cells instead of into T effector cells in vivo.

These antigen-specific Treg cells specifically ameliorated autoimmunity without compromising immune responses to bacterial antigen.

We have thus successfully generated antigen-specific Treg cells with therapeutic activity toward autoimmunity.

The findings may lead to the development of antigen-specific Treg cell-mediated immunotherapy for multiple sclerosis and type 1 diabetes and also other autoimmune diseases.